Wave Life Sciences reported Q3 2026 financials with $431.0M cash and $12M milestone due in 4Q 2026. The company is advancing clinical trials for RNA editing programs WVE-006, WVE-007, and WVE-008, while its proprietary technology yields new development candidates through partnerships including GSK.